Literature DB >> 19248974

Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.

S Serdar Dogan1, Bita Esmaeli.   

Abstract

Imatinib mesylate and perifosine are two relatively new drugs that have improved outcomes for patients with gastrointestinal stromal tumors in recent years. The ocular side effects of these two drugs are discussed in this chapter. The most common ocular side effect associated with imatinib mesylate is periorbital edema. Perifosine has been associated with a ring-shaped perilimbal corneal ulceration that can be treated with topical steroids and topical antibiotics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19248974     DOI： 10.1016/j.hoc.2008.11.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  6 in total

Review 1.  Ectokinases as novel cancer markers and drug targets in cancer therapy.

Authors:  Garif Yalak; Viola Vogel
Journal:  Cancer Med       Date:  2014-12-14       Impact factor: 4.452

2.  Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.

Authors:  Katia Sotelo Monge; Alberto Gálvez-Ruiz; Alberto Alvárez-Carrón; César Quijada; Anna Matheu
Journal:  Saudi J Ophthalmol       Date:  2015-01-06

Review 3.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

Review 4.  Gastrointestinal stromal tumor.

Authors:  Michael Stamatakos; Emmanouel Douzinas; Charikleia Stefanaki; Panagiotis Safioleas; Electra Polyzou; Georgia Levidou; Michael Safioleas
Journal:  World J Surg Oncol       Date:  2009-08-01       Impact factor: 2.754

5.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500

Review 6.  [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Juhong Shi; Meifen Zhang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.